Staff of Reuters 1 minute Read(Includes background and facts from FDA official’s letter) Reuters, July 9 – On Friday, a top official at the US Food and Medicine Administration called for a government investigation of the meetings between the agency’s staff and Biogen Inc that led to the company’s Alzheimer’s disease drug being approved last month. In a letter posted on Twitter, Janet Woodcock, acting commissioner of the Food and Drug Administration (FDA), asked the Office of Inspector General at the Department of Health and Human Services to investigate whether any interactions between FDA staff and Biogen were in violation of the agency’s policies. The FDA has come under fire for approving the medicine without proof of obvious effectiveness against the disease last month. Woodcock had requested an investigation, according to Stat News. (Manas Mishra in Bengaluru contributed reporting; Arun Koyyur edited the piece.)/n
Read More
